NCT02603315View on ClinicalTrials.gov

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Malignant Pleural Mesotheliomas
Interventions
OTHER

marker CD74 and vascular endothelial growth factor VEGF

correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment

Trial Locations (1)

Unknown

Ain Shams University Hospital, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT02603315 - Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM) | Biotech Hunter | Biotech Hunter